FI961804A - Endoteliinireseptoriantagonistit - Google Patents

Endoteliinireseptoriantagonistit Download PDF

Info

Publication number
FI961804A
FI961804A FI961804A FI961804A FI961804A FI 961804 A FI961804 A FI 961804A FI 961804 A FI961804 A FI 961804A FI 961804 A FI961804 A FI 961804A FI 961804 A FI961804 A FI 961804A
Authority
FI
Finland
Prior art keywords
receptor antagonists
endothelin receptor
endothelin
antagonists
receptor
Prior art date
Application number
FI961804A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI961804A0 (fi
Inventor
Hideyuki Saika
Toshiki Murata
Thomas Pitterna
Thomas Frueh
Lene D Svensson
Yoshihiro Urade
Takaki Yamamura
Toshikazu Okada
Original Assignee
Japat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japat Ltd filed Critical Japat Ltd
Publication of FI961804A0 publication Critical patent/FI961804A0/fi
Publication of FI961804A publication Critical patent/FI961804A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI961804A 1993-11-01 1996-04-26 Endoteliinireseptoriantagonistit FI961804A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93810760 1993-11-01
PCT/EP1994/003418 WO1995012611A1 (fr) 1993-11-01 1994-10-17 Antagonistes de recepteur d'endotheline

Publications (2)

Publication Number Publication Date
FI961804A0 FI961804A0 (fi) 1996-04-26
FI961804A true FI961804A (fi) 1996-04-30

Family

ID=8215056

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961804A FI961804A (fi) 1993-11-01 1996-04-26 Endoteliinireseptoriantagonistit

Country Status (12)

Country Link
US (1) US5780498A (fr)
EP (1) EP0728145A1 (fr)
JP (1) JPH09504302A (fr)
AU (1) AU691201B2 (fr)
BR (1) BR9407933A (fr)
CA (1) CA2173875A1 (fr)
FI (1) FI961804A (fr)
IL (1) IL111431A0 (fr)
NO (1) NO961725L (fr)
RU (1) RU2126418C1 (fr)
WO (1) WO1995012611A1 (fr)
ZA (1) ZA948541B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821670A1 (fr) * 1995-04-21 1998-02-04 Novartis AG Amides de n-aroylaminoacide utilises en tant qu'inhibiteurs d'endotheline
AU7130296A (en) * 1995-09-28 1997-04-17 Ciba-Geigy Japan Limited Antagonists of endothelin receptors
IT1291823B1 (it) * 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
GB9708119D0 (en) * 1997-04-22 1997-06-11 Glaxo Group Ltd Chemical compounds
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE19745146A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue pharmazeutisch wirksame Verbindungen, ihre Herstellung und Verwendung
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6423727B1 (en) 1998-04-23 2002-07-23 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
US6426354B1 (en) 1998-04-23 2002-07-30 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
WO1999055726A1 (fr) * 1998-04-23 1999-11-04 Novartis Ag Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
CA2360740A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
EP1452522A3 (fr) * 1999-03-15 2005-02-09 Axys Pharmaceuticals, Inc. Nouveaux composés et composiitons comme inhibiteurs de proteases
KR100679878B1 (ko) * 1999-04-26 2007-02-07 아지노모토 가부시키가이샤 멜라노사이트-자극 호르몬 억제제
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
EP1395571A1 (fr) 2001-06-11 2004-03-10 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a i flavivirus /i
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
ATE443043T1 (de) 2002-11-12 2009-10-15 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7459472B2 (en) 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
GB0514071D0 (en) * 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
US20090012010A1 (en) * 2007-05-18 2009-01-08 Neuromed Phramaceuticals Ltd. Amino acid derivatives as calcium channel blockers
PE20130214A1 (es) * 2010-02-23 2013-03-11 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
WO2014201172A1 (fr) * 2013-06-11 2014-12-18 Receptos, Inc. Nouveaux modulateurs du récepteur glp-1
US10758569B2 (en) 2014-01-13 2020-09-01 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
WO2015106242A2 (fr) * 2014-01-13 2015-07-16 The General Hospital Corporation Composés bisamide utilisés comme effecteurs allostériques pour réduire l'affinité de liaison de l'hémoglobine pour l'oxygène
WO2016201288A1 (fr) * 2015-06-12 2016-12-15 Brown University Nouveaux composés antibactériens et procédés de préparation et d'utilisation de ceux-ci
CN108821994A (zh) * 2018-05-24 2018-11-16 三峡大学 一类双羟基酰氧基双酰胺类药物中间体及其制备方法
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
RU2716258C1 (ru) * 2019-07-30 2020-03-11 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Пептидный антагонист нмда-рецептора
MX2022015207A (es) 2020-06-10 2023-02-13 Aligos Therapeutics Inc Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus.
FR3111544A1 (fr) * 2020-06-18 2021-12-24 Universite Paris-Saclay Nouveaux composés dipeptidiques, leur procédé de fabrication et une nouvelle application thérapeutique de composés dipeptidiques.
RU2769051C1 (ru) * 2021-06-30 2022-03-28 Общество с ограниченной ответственностью "ТЕРРАНОВА КАПИТАЛ" Пептид, улучшающий функциональные свойства эндотелия сосудов, фармацевтическая композиция на его основе и способ ее применения
EP4366831A1 (fr) 2021-07-09 2024-05-15 Aligos Therapeutics, Inc. Composés anti-viraux

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623142B2 (fr) * 1974-07-01 1981-05-29
US4025644A (en) * 1974-12-18 1977-05-24 Daiichi Seiyaku Co., Ltd. Tyrosine derivatives and use
DE2901667A1 (de) * 1979-01-17 1980-07-31 Troponwerke Gmbh & Co Kg Pharmazeutische verwendung von dipeptiden
EP0072058A1 (fr) * 1981-08-10 1983-02-16 Duphar International Research B.V Seringue à compartiments multiples
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
JPS58133260A (ja) * 1982-02-02 1983-08-08 河村　純郎 多段注射器
DE3332633A1 (de) * 1983-09-09 1985-04-04 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Substituierte carbonsaeurederivate, verfahren zu ihrer herstellung, und arzneimittel
EP0212550A3 (fr) * 1985-08-14 1989-05-10 G.D. Searle & Co. Amides dipeptides substitués
CA1297633C (fr) * 1985-09-27 1992-03-17 Shosuke Okamoto Derive phenylalamine et inhibiteur de la proteinase
DE3673317D1 (de) * 1985-10-11 1990-09-13 Duphar Int Res Automatische spritze.
DE3770294D1 (de) * 1986-03-14 1991-07-04 Syntex Inc 3,5-disubstituierte 4,5-dihydroisoxazole als transglutaminasehemmer.
US5187156A (en) * 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
CA1326108C (fr) * 1988-04-12 1994-01-11 Sun Hyuk Kim Antagoniste de la cck
JPH0347163A (ja) * 1989-06-30 1991-02-28 Fujisawa Pharmaceut Co Ltd アントラキノン誘導体およびその製造
CA2032559C (fr) * 1989-12-28 2001-11-06 Kiyofumi Ishikawa Pentapeptides cycliques antagonistes de l'endotheline
US5284828A (en) * 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2043741C (fr) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Derives de peptides antagonistes d'endotheline
DK220890D0 (da) * 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
CA2106764A1 (fr) * 1991-04-24 1992-10-25 David C. Horwell Polypeptides substitues en ó presentant une activite therapeutique
TW270116B (fr) * 1991-04-25 1996-02-11 Hoffmann La Roche
DK0584290T3 (da) * 1991-05-16 2000-12-27 Warner Lambert Co Endothelinantagonister
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
CZ287406B6 (cs) * 1991-11-05 2000-11-15 Smithkline Beecham Corporation Indanové a indenové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
TW224462B (fr) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
JPH07509465A (ja) * 1992-07-17 1995-10-19 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体アンタゴニスト

Also Published As

Publication number Publication date
RU2126418C1 (ru) 1999-02-20
WO1995012611A1 (fr) 1995-05-11
BR9407933A (pt) 1996-11-26
AU7856594A (en) 1995-05-23
CA2173875A1 (fr) 1995-05-11
NO961725D0 (no) 1996-04-29
AU691201B2 (en) 1998-05-14
IL111431A0 (en) 1994-12-29
JPH09504302A (ja) 1997-04-28
EP0728145A1 (fr) 1996-08-28
NO961725L (no) 1996-04-29
US5780498A (en) 1998-07-14
FI961804A0 (fi) 1996-04-26
ZA948541B (en) 1995-05-02

Similar Documents

Publication Publication Date Title
FI961804A0 (fi) Endoteliinireseptoriantagonistit
DK0612244T3 (da) Endothelinreceptorantagonister
DE69327720D1 (de) Endothelin rezeptor antagonisten
FI960953A0 (fi) Endoteliinireseptoriantagonisteja
ATE213156T1 (de) Endothelin-rezeptor-antagonisten
NO972016D0 (no) Indolyl-Y-reseptorantagonister
NO943190L (no) Sulfonamid-endothelin-antagonister
ZA939516B (en) Endothelin receptor antagonists
NO960473D0 (no) Substituerte bifenyl-sulfonamid-endotelin-antagonister
KR960700722A (ko) 피브리노겐 수용체 길항제(Fibrinogen receptor antagonists)
NO20000542L (no) Endothelin-antagonister
BR9507220A (pt) Antagonistas de receptores de endotelina
DE69636597D1 (de) Endothelin rezeptor antagonisten
NO944013D0 (no) Endothelin-antagonister II
BR9603432A (pt) Antagonistas de receptores de endotelina
EP0711157A4 (fr) Antagonistes du recepteur d'endotheline
LV10425A (lv) Fibrinogena receptoru antagonisti